- Home
- BLKB vs LTGO Comparison
BLKB vs LTGO Comparison
Compare BLKB & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BLKB | LTGO |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2004 | 2026 |
Fundamental Metrics
Financial Performance| Metric | BLKB | LTGO |
|---|---|---|
| Price | $47.20 | $24.01 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $50.00 | N/A |
| AVG Volume (30 Days) | ★ 579.0K | 324.4K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.32 | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.26 | N/A |
| Revenue Next Year | $4.25 | N/A |
| P/E Ratio | $32.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.58 | $17.22 |
| 52 Week High | $70.71 | $25.00 |
Technical Indicators
Market Signals| Indicator | BLKB | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 68.72 | 85.87 |
| Support Level | $45.83 | $18.46 |
| Resistance Level | $50.76 | $25.00 |
| Average True Range (ATR) | 1.82 | 1.44 |
| MACD | -0.25 | 0.49 |
| Stochastic Oscillator | 89.16 | 88.95 |
Price Performance
Historical ComparisonAbout BLKB Blackbaud Inc.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.